M&A / Deals Metsera backers establish new biotech armed with China-licensed immunology asset Pharmaceutical TechnologyPHP and ARCH have established Sentivera, a biotech that now has an immunology licensing deal with China-based Haisco.Immunology & InflammationRead full story pharminent August 26, 2026 (Last updated: September 1, 2026) Pharmaceutical Technology PHP and ARCH have established Sentivera, a biotech that now has an immunology licensing deal with China-based Haisco. Immunology & Inflammation Read full story Post navigation Previous: Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2Next: Spyre deprioritises arthritis drug after Phase 2 results Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026